Sector Expert: Jay Albany

SeeThruEquity

Image: Jay Albany

Jay Albany, CFA, has more than a decade's experience conducting equity research and analysis in life sciences and other high tech industries. He is a senior analyst at SeeThruEquity LLC, after a stint as senior vice president of equity research. Previously, Albany served as senior vice president of capital markets at Emissary Capital LLC, after working as a research analyst at Skellig Capital LLC and as a security analyst at Calisto Capital Management Inc. He began his financial services career at kozmo.com as manager of business development. Albany is a member of the New York Society of Securities Analysts and is a CFA charterholder. He earned a bachelor of arts degree from Columbia University.

Subscribe to
Streetwise Reports

Companies Commented On

  • Innovus Pharmaceuticals Inc.


Recent Interviews

Eight Ways to Leverage the Small-Cap Biotech Bull Market: Ajay Tandon and Jay Albany of SeeThruEquity (10/28/15)
BalanceMoneyandPills580

SeeThruEquity's Ajay Tandon and Jay Albany are riding the biotech bull by harnessing the huge upside potential of micro-cap companies working in multiple subsectors, particularly in the rapidly advancing cancer immunotherapy sector. In this interview with The Life Sciences Report, Tandon and Albany toss the names of several companies into the arena for investors' consideration.

Recent Quotes

"INNV has been developing a promising growth engine in what appears to be a replicable process of identifying promising OTC products that target large markets—and then leveraging its Beyond Human sales platform."

— Jay Albany, SeeThruEquity (8/9/17)
more >

"We find RESX to be a worthwhile investment."

The Life Sciences Report Interview with Jay Albany (10/28/15)
more >

"CYP's lead medical technology platform has very exciting potential."

The Life Sciences Report Interview with Jay Albany (10/28/15)
more >

"We've seen a lot of acceleration for AEMD since the Hemopurifier was used successfully to treat an Ebola patient in Germany."

The Life Sciences Report Interview with Jay Albany (10/28/15)
more >



Due to permission requirements, not all quotes are shown.